Cara Therapeutics 過去の業績
過去 基準チェック /06
Cara Therapeutics's earnings have been declining at an average annual rate of -9%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 10.4% per year.
主要情報
-9.0%
収益成長率
-1.5%
EPS成長率
Pharmaceuticals 業界の成長 | 6.0% |
収益成長率 | -10.4% |
株主資本利益率 | -957.8% |
ネット・マージン | -1,010.2% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues
Nov 01Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jul 18We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope
May 29Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S
May 25We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19収支内訳
Cara Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 11 | -111 | 27 | 0 |
31 Mar 24 | 17 | -123 | 29 | 0 |
31 Dec 23 | 21 | -119 | 29 | 0 |
30 Sep 23 | 21 | -117 | 29 | 0 |
30 Jun 23 | 27 | -112 | 29 | 0 |
31 Mar 23 | 43 | -84 | 29 | 0 |
31 Dec 22 | 42 | -85 | 31 | 0 |
30 Sep 22 | 39 | -89 | 36 | 0 |
30 Jun 22 | 49 | -66 | 35 | 0 |
31 Mar 22 | 26 | -93 | 34 | 0 |
31 Dec 21 | 23 | -88 | 31 | 0 |
30 Sep 21 | 134 | 24 | 25 | -6 |
30 Jun 21 | 123 | 8 | 25 | 0 |
31 Mar 21 | 129 | 14 | 24 | 0 |
31 Dec 20 | 135 | 8 | 23 | 0 |
30 Sep 20 | 28 | -99 | 20 | 6 |
30 Jun 20 | 24 | -115 | 19 | 0 |
31 Mar 20 | 24 | -113 | 18 | 0 |
31 Dec 19 | 20 | -106 | 18 | 0 |
30 Sep 19 | 21 | -98 | 18 | 0 |
30 Jun 19 | 20 | -85 | 17 | 0 |
31 Mar 19 | 18 | -79 | 16 | 0 |
31 Dec 18 | 13 | -74 | 15 | 0 |
30 Sep 18 | 8 | -68 | 14 | 0 |
30 Jun 18 | 3 | -61 | 14 | 0 |
31 Mar 18 | 0 | -53 | 13 | 0 |
31 Dec 17 | 1 | -58 | 12 | 0 |
30 Sep 17 | 1 | -66 | 11 | 0 |
30 Jun 17 | 1 | -65 | 9 | 0 |
31 Mar 17 | 1 | -69 | 9 | 0 |
31 Dec 16 | 0 | -57 | 9 | 0 |
30 Sep 16 | 0 | -45 | 9 | 0 |
30 Jun 16 | 3 | -38 | 9 | 0 |
31 Mar 16 | 3 | -31 | 8 | 0 |
31 Dec 15 | 4 | -25 | 8 | 0 |
30 Sep 15 | 5 | -19 | 7 | 0 |
30 Jun 15 | 3 | -21 | 7 | 0 |
31 Mar 15 | 3 | -19 | 7 | 0 |
31 Dec 14 | 3 | -18 | 6 | 0 |
30 Sep 14 | 3 | -16 | 5 | 1 |
30 Jun 14 | 3 | -14 | 5 | 2 |
31 Mar 14 | 12 | -6 | 4 | 3 |
31 Dec 13 | 12 | -3 | 4 | 0 |
質の高い収益: CARA is currently unprofitable.
利益率の向上: CARA is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CARA is unprofitable, and losses have increased over the past 5 years at a rate of 9% per year.
成長の加速: Unable to compare CARA's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: CARA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
株主資本利益率
高いROE: CARA has a negative Return on Equity (-957.76%), as it is currently unprofitable.